Drugs / TC-510
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05451849 | Jun 2022 → Aug 2025 | cholangiocarcinoma, colorectal cancer, malignant mesothelioma, non-small cell lung carcinoma +5 | TCR2 Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05451849 ↗ |
| Modality | Cell therapy | “TC-510 is a novel cell therapy” NCT05451849 ↗ |